Estamos no ar no ! Saiba mais

PetMed Express

PETS

Valor de mercado US$ 25,6 mi

1,18 USD

-0,04

3,28%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

-3,28%

5 dias

-7,09%

1 mês

-26,25%

3 meses

-41%

6 meses

-49,57%

No acumulado do ano

-64,24%

1 ano

-53,54%

5 anos

-95,63%

10 anos

-94,29%

Sobre: PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.

Funcionários: 189

Saúde Varejo farmacêutico

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 90%

Negativo 10%

PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.

PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director

Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution

PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director

PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition

Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement

PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition

PetMeds Appoints Andrew Parry as Chief Technology Officer

DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the Company's technology strategy, platform architecture and engineering execution across its e-commerce, pharmacy and enterprise systems.

PetMeds Appoints Andrew Parry as Chief Technology Officer

Zacks Investment Research

PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y

PETS' fiscal first-quarter 2027 sales decline year over year, but lower costs, stronger recurring sales and new partnerships offer signs of progress.

PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y

Zacks Investment Research

PetMed (PETS) Reports Q1 Loss, Misses Revenue Estimates

PetMed (PETS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of $0.12. This compares to a loss of $0.34 per share a year ago.

PetMed (PETS) Reports Q1 Loss, Misses Revenue Estimates

PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript

PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript

PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript

PetMeds® Announces First Quarter Financial Results

DELRAY BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026.

PetMeds® Announces First Quarter Financial Results

PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026

DELRAY BEACH, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the first quarter fiscal year ended June 30, 2026, on Thursday, August 13, 2026 after market close. The Company will host a conference call and webcast to review these results at 4:30pm Eastern Time on the same day.

PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026

PetMeds Announces Proposed Sale-Leaseback of Headquarters and Distribution Center Buildings for $37 Million

DELRAY BEACH, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that it has entered into a definitive agreement for a sale-leaseback transaction (“Transaction”) with an institutional real estate investor involving the Company's headquarters and distribution center buildings in Delray Beach, FL, for an aggregate purchase price of $37 million.

PetMeds Announces Proposed Sale-Leaseback of Headquarters and Distribution Center Buildings for $37 Million

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™